Skip to main content
. Author manuscript; available in PMC: 2022 May 16.
Published in final edited form as: Cancer Drug Resist. 2022 Jan 4;5:80–89. doi: 10.20517/cdr.2021.112

Figure 3.

Figure 3.

Development of resistance to VAC treatment (decreases in EFS) in models that were intrinsically sensitive to treatment (> PR; Rh88, Rh30R, IRS-68) or models where tumors progressed through cycle 1 of VAC treatment (Rh72, Rh73). VAC: Vincristine/actinomycin-D/cyclophosphamide; EFS: event-free survival; PR: partial response.